McKesson Corporation (MCK)

McKesson's stock reached all-time highs in October 2025, with shares increasing to $800.00 USD on October 24, 2025, and $794.00 USD on October 22, 2025. Analysts have shown strong positive sentiment, with multiple firms raising their price targets for MCK. McKesson announced its intention to separate its Medical-Surgical Solutions segment into an independent company in May 2025. The company declared a regular quarterly dividend of $0.71 per share in May 2025, later increased to $0.82 per share. In August 2025, McKesson reported better-than-expected revenue for Q2 CY2025, with sales up 23.4% year-on-year. McKesson completed the divestiture of its Canada-based Rexall and Well.ca retail businesses on December 30, 2024.

McKesson actively manages and accounts for demand seasonality in its operations by utilizing expanded data sets and proprietary machine learning algorithms to detect patient dispense demand patterns, seasonality, and volatility. This allows McKesson to more accurately forecast demand fluctuations, identify at-risk items, and ensure inventory is available at the right place and time.

McKesson Corporation operates in the healthcare sector, focusing on wholesale drugs, proprietaries, druggists' sundries, and medical distributors. It distributes pharmaceuticals and medical supplies and provides health information technology and health management tools. The company's core business segments include U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs to various healthcare providers across North America. It also provides medical and surgical products, logistics, and biomedical equipment maintenance to healthcare providers. McKesson offers technology-driven solutions to enhance healthcare delivery and operational efficiency, including prescription price transparency and dispensing support services. Additionally, it provides distribution and services to customers in Canada and 13 European countries.

McKesson has a significant global presence in North America, Europe, and other regions. The United States is its largest market, representing over 80% of its total revenue. The company also has a substantial footprint in Canada and across 13 European countries.

McKesson has maintained a positive brand reputation, marked by several achievements and strategic initiatives. McKesson was recognized as a "Best Place to Work for Disability Inclusion" for the ninth consecutive year. McKesson launched InspiroGene, a dedicated business focused on supporting the commercialization of cell and gene therapies. Ontada, McKesson's oncology technology and insights business, announced a strategic collaboration with Datavant to integrate Ontada's data into Datavant's health ecosystem and also collaborated with Microsoft to leverage Azure AI. The company's strategic divestiture of its Canadian retail businesses was aimed at prioritizing investments in higher-growth areas.

Institutional investors hold a significant portion of McKesson Corp. shares, accounting for 72.9% of the total. State Street Corp. is a major institutional owner, holding 4.55% of the shares. Other notable institutional holders include Manulife Financial Corp., Swedbank AB, and Schweizerische Nationalbank. Individuals hold a smaller percentage, at 0.02%.